Sellas' Cancer Vaccine Cuts Death Risk By 41% In Phase 3 Leukemia Trial
SELLAS Life Sciences (SLS) reported that its cancer vaccine, galinpepimut-S, met the primary survival endpoint in a Phase 3 trial for acute myeloid leukemia. The vaccine reduced death risk by 41% compared to standard treatment, with median survival of 24 months versus 14.7 months. The company plans to discuss FDA filing strategy in 2027. SLS shares rose 7.10% in pre-market trading.
How this was made

The 30-second read
Why it matters
The disclosed primary endpoint success (overall survival) with a reported 41% reduction in death risk and median OS improvement is a material de-risking event for SELLAS, shifting focus to FDA engagement and the planned biologics license application preparations in 1H 2027.
Market read
Traders can reassess approval probability and timeline expectations based on the reported overall survival benefit and the stated plan to meet the FDA and prepare a BLA in 1H 2027.
What to watch
The article does not quantify effect robustness across secondary endpoints or provide hazard ratios, statistical significance details, or comparator specifics beyond “investigator-selected best available treatment,” which can matter for regulatory and market follow-through.
Background
Galinpepimut-S (GPS) is an investigational cancer vaccine intended to stimulate an immune response against WT1-expressing AML cells; it is being advanced in a pivotal Phase 3 REGAL trial for patients in second or later remission who cannot undergo allogeneic stem-cell transplant.
Ticker impact
SELLAS reported Phase 3 REGAL trial success for galinpepimut-S, saying it met the primary overall survival endpoint and cut death risk by 41%.
Likely upward bias as traders price in higher odds for a 2027 FDA biologics license application, despite remaining uncertainty around confirmatory details and FDA review.
The article provides specific efficacy magnitude (41% death-risk reduction, median OS 24 vs 14.7 months) plus a concrete next step (FDA meeting and BLA preparations in 1H 2027), which are decision-relevant for biotech risk.
Market effects
Reinforces investor appetite for WT1-targeted immunotherapies and AML maintenance strategies, potentially lifting sentiment across small-cap oncology vaccine/biotech peers.
Primarily US small-cap biotech sentiment; limited direct cross-region spillover implied by the company-specific trial update.
Moderate global relevance for AML treatment development, but the catalyst is company-specific and tied to US FDA filing strategy.
Counterpoint
A Phase 3 overall survival endpoint meeting headline does not guarantee FDA approval; open-label design, patient selection, and future subgroup/confirmatory analyses could temper enthusiasm.
Key entities
- companySELLAS Life Sciences Group, Inc.
Sponsor of the investigational AML vaccine galinpepimut-S and reporter of Phase 3 REGAL overall survival results.
- productGalinpepimut-S (galinpepimut-S, GPS)
Investigational cancer vaccine designed to target WT1-expressing cancer cells.
- clinical_trialREGAL trial
Pivotal Phase 3 study in acute myeloid leukemia reporting overall survival as the primary endpoint.
- regulatorFDA
Planned meeting target to discuss filing strategy and biologics license application preparations.

